

## Thyroid Disorders: Review of Drug Therapy and Monitoring Strategies

Bharat Mishra

Professor & Director, Department of Pharmacy, Dr. Shakuntala Misra National Rehabilitation University, Lucknow.

**Article History:** Received: 03 Feb 2025, Revised: 26 Feb 2025, Accepted: 16 Apr 2025

**\*Corresponding author**

Prof. Dr. Bharat Mishra

### Abstract

Thyroid disorders, encompassing hypothyroidism and hyperthyroidism, represent some of the most prevalent endocrine diseases worldwide. They profoundly impact metabolic, cardiovascular, skeletal, and neurocognitive systems. Effective management depends on accurate diagnosis, individualized pharmacotherapy, and structured biochemical and clinical monitoring. This review comprehensively examines the pharmacologic management of thyroid disorders, focusing on the pharmacokinetics, therapeutic efficacy, adverse effect profiles, and monitoring strategies of levothyroxine, methimazole, and propylthiouracil. It also highlights drug–disease interactions, monitoring intervals, and clinical considerations in special populations such as the elderly, pregnant women, and those with comorbidities. Practical recommendations for therapy optimization, safety surveillance, and follow-up are provided, along with recent evidence on long-term outcomes and emerging monitoring challenges.

**Keywords:** Hypothyroidism, Hyperthyroidism, Levothyroxine, Methimazole, Propylthiouracil, Thyroid-stimulating hormone, Monitoring, Antithyroid drugs

This article is licensed under a Creative Commons Attribution-Non-commercial 4.0 International License.  
Copyright © 2026 Author(s) retains the copyright of this article.



### INTRODUCTION

Thyroid hormones play a central role in regulating metabolism, growth, and development. Disorders of thyroid function, including hypothyroidism and hyperthyroidism, are common, affecting an estimated 5–10% of the population worldwide [1]. Hypothyroidism results from reduced production of thyroid hormones, whereas hyperthyroidism (or thyrotoxicosis) is due to excessive secretion or action of these hormones [2]. Both conditions are associated with significant morbidity, ranging from cardiovascular and skeletal complications to metabolic dysregulation. Pharmacotherapy remains the cornerstone of thyroid disorder management. The goals are to restore or maintain euthyroidism, alleviate symptoms, and prevent long-term complications. Regular monitoring of biochemical parameters, clinical signs, and potential drug-induced adverse effects ensures optimal outcomes [3,4]. This review focuses on the pharmacological management and evidence-based monitoring strategies for thyroid disorders, highlighting best practices and current clinical guidelines.

### PATHOPHYSIOLOGY AND RATIONALE FOR DRUG THERAPY

Thyroid hormone synthesis and secretion are regulated by the hypothalamic–pituitary–thyroid axis. Thyrotropin-releasing hormone (TRH) from the hypothalamus stimulates the pituitary to release thyroid-stimulating hormone (TSH), which, in turn, promotes synthesis and release of thyroxine (T<sub>4</sub>) and triiodothyronine (T<sub>3</sub>) from the thyroid gland. T<sub>4</sub> is largely a prohormone that undergoes peripheral conversion to the biologically active T<sub>3</sub> [5].

Drug therapy for thyroid disorders aims either to replace deficient hormone levels in hypothyroidism or to suppress excessive hormone production in hyperthyroidism. The feedback sensitivity of TSH makes it the most useful biomarker for assessing adequacy of treatment [1,6].

### HYPOTHYROIDISM: DRUG THERAPY

#### Levothyroxine: The Cornerstone of Therapy

Levothyroxine (L-T<sub>4</sub>) remains the gold-standard therapy for hypothyroidism [1,7]. It is a synthetic form of T<sub>4</sub> that undergoes peripheral conversion to T<sub>3</sub>, maintaining stable physiological levels of both hormones. The typical full replacement dose for adults is approximately 1.6 µg/kg/day, though lower initial

doses (12.5–50 µg/day) are recommended in elderly patients and those with cardiac disease [8,9].

#### Pharmacokinetics and Dosing Considerations

Levothyroxine has an elimination half-life of 7 days, allowing once-daily dosing. Absorption occurs primarily in the jejunum and ileum and is influenced by gastric pH and concurrent ingestion of food, calcium, iron, and proton pump inhibitors [10]. Thus, patients are advised to take levothyroxine on an empty stomach, ideally 30–60 minutes before breakfast. Pregnant women often require a dose increase of 30–50% early in pregnancy due to elevated estrogen levels and increased thyroid-binding globulin [11]. In the elderly, slower titration is necessary to prevent cardiac arrhythmias and ischemic events [12].

#### Treatment Goals and Monitoring

The primary therapeutic goal is normalization of serum TSH and free T4 concentrations. TSH should be rechecked 6–8 weeks after dose initiation or adjustment [13]. Once stable, annual monitoring suffices for most patients. Persistent symptoms despite normal TSH may indicate inadequate tissue-level conversion, poor absorption, or comorbid non-thyroidal illness [14].

#### Adverse Effects and Drug Interactions

Excessive levothyroxine dosing can result in iatrogenic thyrotoxicosis, leading to atrial fibrillation, anxiety, tremor, and accelerated bone loss [15,16]. Underdosing may perpetuate hypothyroid symptoms such as fatigue, weight gain, and dyslipidemia [1]. Drug interactions with calcium, iron, and antacids are common and must be managed carefully [10,17].

#### Combination and Alternative Therapies

Although combination T4/T3 therapy and desiccated thyroid extract have gained popularity, clinical trials have not shown consistent benefits over monotherapy [18]. Guidelines recommend levothyroxine monotherapy as first-line, reserving combination therapy for selected patients under close supervision [19].

### HYPERTHYROIDISM: DRUG THERAPY

#### Thionamides (Methimazole and Propylthiouracil)

The thionamides-methimazole (MMI), carbimazole (its prodrug), and propylthiouracil (PTU)-are the mainstay pharmacologic treatments for hyperthyroidism [2,20]. They inhibit thyroid peroxidase, blocking iodine organification and coupling reactions. PTU also inhibits peripheral conversion of T4 to T3 [21].

#### Drug Selection and Dosing

Methimazole is generally preferred due to its longer half-life, once-daily dosing, and lower hepatotoxicity risk [22]. PTU is reserved for first-trimester pregnancy or thyroid storm because of rare but severe hepatotoxicity [23]. Typical initial doses: methimazole 20–40 mg/day and PTU 300 mg/day, with gradual reduction as euthyroidism is achieved [24].

#### Duration and Monitoring

In Graves' disease, thionamide therapy is typically continued for 12–18 months, after which remission rates of 40–60% are observed [25]. Baseline TSH, free T4, free T3, liver enzymes, and complete blood count (CBC) should be obtained before initiation. Follow-up every 4–6 weeks with free T4/free T3 measurement is recommended until euthyroid state is achieved [2,11].

#### Adverse Effects

Common side effects include rash, arthralgia, and gastrointestinal discomfort [20]. Severe but rare complications include agranulocytosis and hepatotoxicity. Patients should be instructed to report fever, sore throat, or jaundice immediately [6,23]. Routine CBC monitoring is not indicated unless symptoms arise.

#### Adjunctive Therapies

β-blockers such as propranolol are used for symptomatic relief of tremor, palpitations, and anxiety [24]. Iodide preparations (e.g., Lugol's solution) and glucocorticoids serve as adjuncts in thyroid storm or preoperative preparation.

### MONITORING STRATEGIES

#### Monitoring in Hypothyroidism

**Initial testing:** Baseline TSH, free T4, lipid profile, and ECG in patients with cardiac risk [8].

**Follow-up:** Repeat TSH and free T4 after 6–8 weeks of therapy or dose change [1].

**Stable state:** Once euthyroid, annual testing is sufficient [13].

**Pregnancy:** Monitor TSH every 4 weeks during the first half of pregnancy and at least once per trimester thereafter [11].

**Elderly:** Assess cardiac rhythm, bone density, and cognitive status periodically [12,15].

#### Monitoring in Hyperthyroidism

**Baseline:** TSH, free T4/free T3, CBC, and liver enzymes [23].

**Early follow-up:** Recheck free T4/free T3 every 4–6 weeks; TSH may remain suppressed early on [2].

**Maintenance:** Every 2–3 months once euthyroid.

**Adverse effect surveillance:** Educate patients on early warning signs of agranulocytosis and hepatotoxicity [6,20].

**Remission assessment:** Measure thyroid-stimulating immunoglobulin (TRAb) before stopping therapy; persistently high TRAb predicts relapse [25].

### LONG-TERM OUTCOMES

Long-term monitoring is essential because overtreatment with thyroid hormones increases cardiovascular risk and accelerates bone loss [15,16]. Conversely, undertreatment of hypothyroidism may exacerbate dyslipidemia and coronary disease [8]. Postmenopausal women on levothyroxine require periodic bone density assessment [19].

## SPECIAL POPULATIONS

### Pregnancy

Maternal thyroid hormones are crucial for fetal neurodevelopment. Hypothyroid women require increased levothyroxine doses early in gestation [11]. In hyperthyroid women, PTU is preferred in the first trimester due to teratogenic risk with methimazole, after which methimazole is safer (23). Frequent biochemical monitoring (every 2–4 weeks) is required to maintain euthyroidism without fetal exposure to excess antithyroid drugs.

### Elderly Patients

Older adults often have atypical presentations, such as apathy or weight loss without tachycardia (12). They are more vulnerable to cardiac complications and drug interactions. Lower starting doses of levothyroxine and careful monitoring are mandatory.

### Cardiac Disease

Thyroid dysfunction significantly impacts cardiac function. Hyperthyroidism increases myocardial oxygen demand and arrhythmia risk, while hypothyroidism elevates serum cholesterol and reduces contractility (15). ECG monitoring and cautious dose titration are crucial in patients with cardiovascular disease.

### Subclinical Thyroid Disorders

Treatment of subclinical hypothyroidism (TSH >10 mIU/L) is generally recommended, especially in symptomatic patients or those with cardiovascular risk (8). Subclinical hyperthyroidism requires treatment in elderly or osteoporotic individuals due to increased risk of atrial fibrillation and fractures (16).

## EMERGING ISSUES AND MONITORING CHALLENGES

Despite standardized biochemical targets, many patients continue to experience symptoms even after achieving euthyroid TSH levels (14). Genetic polymorphisms affecting deiodinase activity and thyroid hormone transport may influence therapeutic response (18). The impact of long-term levothyroxine use on bone and cardiovascular outcomes has been increasingly recognized [7, 19, 23].

Monitoring also needs to account for external factors such as immunotherapy-induced thyroid dysfunctions (13) and new drugs affecting thyroid function (5). A patient-centered approach combining clinical, biochemical, and functional assessment is essential.

## PRACTICAL MONITORING CHECKLIST

- Baseline:** TSH, free T4, free T3, CBC, liver function tests, lipid profile.
- Levothyroxine users:** Reassess TSH after 6–8 weeks; adjust dose in 12.5–25 µg increments.
- Antithyroid therapy:** Monitor free T4/T3 every 4–6 weeks; observe for adverse effects.
- Special populations:** Pregnancy-monitor monthly; elderly-monitor cardiac and bone health.
- Adherence and interactions:** Counsel patients on correct timing, diet, and co-administered drugs.

- Annual review:** TSH, bone density (if high risk), ECG, lipid profile, and hepatic function where appropriate.

## CONCLUSION

Thyroid disorders demand meticulous pharmacologic management and individualized monitoring. Levothyroxine remains the therapy of choice for hypothyroidism, requiring careful titration and attention to drug interactions. Antithyroid agents, particularly methimazole, effectively manage hyperthyroidism, but vigilance for adverse effects such as agranulocytosis and hepatotoxicity is essential. Monitoring strategies must extend beyond biochemical normalization to include patient symptoms, cardiovascular status, and bone health. Optimized therapy, patient education, and evidence-based follow-up are pivotal to achieving long-term euthyroidism and preventing complications. Ongoing research into personalized thyroid hormone replacement and improved monitoring biomarkers will likely refine therapeutic paradigms in the coming years.

## REFERENCES

- Wilson SA, McAninch EA. Hypothyroidism: Diagnosis and Treatment. *Am Fam Physician*. 2021;103(10):605-613.
- Kravets I, Alexander E, Solomon B. Hyperthyroidism: Diagnosis and Treatment. *Am Fam Physician*. 2016;93(6):363-371.
- NICE. Thyroid disease: assessment and management. London: National Guideline Centre (UK); 2019.
- Murthy MB. Thyroid: Disorders, disruptors and drugs. *Indian J Endocrinol Metab*. 2013;17(2):208-217.
- Gschmeissner S. Thyroid dysfunction and drug interactions. *Pharm J*. 2021.
- Awosika AO, Giudice L, Wolff M. Methimazole. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
- Li X, Zhang T, Zhang H, Liu S, Tian L. Effects of levothyroxine therapy on bone and mineral metabolism in hypothyroidism: a systematic review. *BMC EndocrDisord*. 2025;25:11.
- Hughes K, Eastman C. Thyroid disease: Long-term management of hyperthyroidism and hypothyroidism. *Aust J Gen Pract*. 2021;50(1-2):8-13.
- Colucci P, Seng Yue C, Ducharme M, Benvenga S. A review of the pharmacokinetics of levothyroxine for hypothyroidism. *Adv Ther*. 2018;35(11):1745-1765.
- Dong BJ. How medications affect thyroid function. *EndocrPract*. 2000;6(6):512-523.
- Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults. *Thyroid*. 2012;22(12):1200-1235.

12. Effraimidis G, et al. Levothyroxine therapy in elderly patients with thyroid disease. *Front Endocrinol (Lausanne)*. 2021;12:641560.
13. Baraka B, Abosheishaa H, Nassar M. Immunotherapy-induced thyroid dysfunction. *Egypt J Intern Med*. 2023;35:48.
14. McAninch EA, Bianco AC. Evaluating health outcomes in the treatment of hypothyroidism. *Front Endocrinol (Lausanne)*. 2022;13:1026262.
15. Hong AR, et al. Evaluation and management of bone health in patients with thyroid disease. *Endocrinol Metab*. 2023;38(3):170-185.
16. Teng W. Levothyroxine and bone. In: *Endotext* [Internet]. MDText.com; 2021.
17. Ghotbi E, et al. Common thyroid medicine linked to bone loss. *RSNA Press Release*. 2024 Nov 25.
18. Jonklaas J, et al. Evidence-based use of combination therapy for hypothyroidism. *Thyroid*. 2021;31(2):156-182.
19. Apaydin M, et al. Evaluation of bone health in postmenopausal women receiving levothyroxine. *J Osteoporos*. 2024;2024:11648544.
20. Abdi H, Amouzegar A, Azizi F. Antithyroid Drugs. *Iran J Pharm Res*. 2019;18(Suppl 1):e124684.
21. Li X, Chen L, Jin L, Fu X. Efficiency and safety of methimazole and propylthiouracil. *Medicine (Baltimore)*. 2021;100(30):e26707.
22. Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 ETA Guidelines for Graves' Hyperthyroidism. *Eur Thyroid J*. 2018;7(4):167-186.
23. Fredette ME, et al. Methimazole-induced agranulocytosis in a pediatric patient. *Horm Res Paediatr*. 2025;98(2):156-163.
24. Shah R. Management aspects of medical therapy in Graves' disease. *Clin ObstetGynecolReprod Med*. 2024;12:100389.
25. Dagnev FN, Wondm SA, Mengistu ME, et al. Drug-related problems among thyroid disorder patients. *Sci Rep*. 2025;15:27132.